Given Roche???s expertise in diagnostics, genomics and drug discovery ??? there are 68 new molecular entities in its pharma pipeline ??? shareholders could be handsomely rewarded in coming years as the company expands its leadership position from oncology to related fields, such as immunology and neuroscience.